Survanta Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The survanta market research report is one of a series of new reports that provides survanta market statistics, including the survanta industry global market size, regional shares, competitors with the survanta market share, detailed survanta market segments, market trends, and opportunities, and any further data you may need to thrive in the survanta industry. This survanta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecasted rising prevalence of respiratory disorders in neonates, advancements in surfactant therapy, increasing government initiatives for neonatal health, growth in neonatal intensive care units (NICUs), and expanding healthcare access in emerging markets. Major trends include advancements in neonatal care, technological innovations, point-of-care diagnostics, telemedicine in neonatal care, and personalized medicine.

The increasing prevalence of premature births is expected to significantly contribute to the growth of the Survanta market in the coming years. Premature births, which occur when a baby is born before 37 weeks of pregnancy, result in underdeveloped organs and higher health risks. Factors such as advanced maternal age, lifestyle choices, the rise of chronic conditions, and advancements in fertility treatments have contributed to the growing number of premature births. Survanta is used to treat respiratory distress syndrome (RDS) in premature infants, a condition common due to insufficient surfactant production in their lungs. By improving lung function, it helps reduce the risk of complications. For example, the Centers for Disease Control and Prevention (CDC) reported that in 2022, the percentage of premature live births in England and Wales increased to 7.9%, up from 7.5% in 2021. This rising prevalence of premature births is driving the growth of the Survanta market.

Increased investments in maternal and child health are anticipated to further boost the growth of the Survanta market. Maternal and child health encompasses the well-being of women during pregnancy, childbirth, and the postpartum period, as well as the health and development of children, especially in their early years. Growing investments in this area aim to reduce maternal and infant mortality, improve healthcare access, and promote long-term social and economic development. These investments help ensure access to vital treatments such as Survanta, which is essential in reducing neonatal mortality from respiratory distress syndrome. For instance, the American Hospital Association reported in September 2024 that the U.S. Department of Health and Human Services allocated over $558 million to maternal health initiatives, including $440 million for home visiting services and $118.5 million for CDC programs. As a result, the increasing focus on maternal and child health is driving the growth of the Survanta market.

The rising number of infant hospital admissions is also expected to drive the growth of the Survanta market. This increase can be attributed to factors such as higher rates of premature births, more prevalent neonatal and respiratory conditions, improved survival rates that require more complex care, and better access to healthcare facilities. Survanta is commonly used during infant hospitalizations to treat respiratory distress syndrome (RDS) in premature infants, aiding in lung function and minimizing complications. According to the Office for Health Improvement and Disparities, hospital admissions for infants under 14 days in the UK increased from 81.6 per 1,000 population in 2022 to 84.8 per 1,000 population in 2023. This growing number of infant hospital admissions is contributing to the expansion of the Survanta market.

The key company operating in the survanta market is AbbVie Ltd.

North America was the largest region in the survanta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in survanta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the survanta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Survanta is a surfactant medication used to treat or prevent respiratory distress syndrome (RDS) in premature infants. It functions by replacing the natural surfactant in the lungs, reducing surface tension in the alveoli, which in turn improves breathing and enhances oxygen exchange. The medication is delivered directly into the lungs to support their function and ensure respiratory stability.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Survanta is primarily indicated for conditions such as respiratory distress syndrome (RDS), meconium aspiration syndrome (MAS), bronchopulmonary dysplasia (BPD), acute respiratory failure, and other related disorders. RDS is a common condition in premature infants, where the lungs lack adequate surfactant, causing breathing difficulties and insufficient oxygen exchange. Survanta is distributed through various channels, including hospital pharmacies, retail pharmacies, and public health clinics, and is used in pediatric care.

The survanta market consists of sales of surfactant delivery devices, neonatal respiratory care kits, syringes, and injection systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.